{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:28:52Z","timestamp":1773296932498,"version":"3.50.1"},"reference-count":59,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study was designed to assess the clinical efficacy and toxicity of apatinib (YN968D1) as third or subsequent\u2010line treatment for stage III\/IV non\u2010small cell lung cancer (NSCLC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 100 patients with advanced NSCLC who were treated with apatinib at a daily dose of 250\/425\/500 mg at Shandong Cancer Hospital from January 2016 to June 2018 were enrolled in our study. The objective response, disease control, and median progression\u2010free survival rates were reviewed and evaluated. Univariate and multivariate analyses were performed to determine the prognostic factors. The main adverse events were evaluated per the Common Terminology Criteria for Adverse Events version 4.0.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All patients were assessable for response. No complete responses were observed, 11 patients achieved a partial response, and 56 showed stable disease. The objective response rate was 11.0%, the disease control rate was 67.0%, and the median progression\u2010free survival was 2.93 months (95% confidence interval 2.07\u20133.87). In Cox regression analysis, the Eastern Cooperative Oncology Group performance status score (hazard ratio 1.799; <jats:italic>P<\/jats:italic> &lt; 0.05) and smoking history (hazard ratio 1.958; <jats:italic>P<\/jats:italic> &lt; 0.05) were predictive indicators for apatinib treatment efficacy. Treatment\u2010related adverse events were tolerated, predictable, reversible, and controllable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Apatinib was found to be both effective and safe in advanced NSCLC patients without a genetic driver mutation who experienced progression after two or more lines of chemotherapy treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.12898","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T10:34:26Z","timestamp":1539945266000},"page":"1754-1762","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III\/IV non\u2010small cell lung cancer after second\u2010line chemotherapy treatment: A retrospective study"],"prefix":"10.1111","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8960-2264","authenticated-orcid":false,"given":"Di","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University Shandong University  Jinan China"},{"name":"Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences Shandong Cancer Hospital and Institute  Jinan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chufeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences Shandong Cancer Hospital and Institute  Jinan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University Shandong University  Jinan China"},{"name":"Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences Shandong Cancer Hospital and Institute  Jinan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences Shandong Cancer Hospital and Institute  Jinan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qisen","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences Shandong Cancer Hospital and Institute  Jinan China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,10,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442"},{"key":"e_1_2_7_3_1","article-title":"A retrospective study of concurrent radiotherapy plus S\u20101 for treating advanced non\u2010small cell lung cancer","volume":"97","author":"Zhao D","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S109683"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60735-0"},{"key":"e_1_2_7_6_1","first-page":"1943","article-title":"Clinical effectiveness of pemetrexed combined with cisplatin chemotherapy for advanced and maintenance treatment for patients with non\u2010small\u2010cell lung cancer","volume":"22","author":"Zhu YM","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0277-y"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0050"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0345"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12661"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2012.05.003"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.196"},{"key":"e_1_2_7_13_1","first-page":"649","article-title":"The need for third\u2010line treatment in non\u2010small cell lung cancer: An overview of new options","volume":"31","author":"Syrigos KN","year":"2011","journal-title":"Anticancer Res"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1862-5"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197111182852108"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.2.11360"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.4174\/astr.2015.89.1.1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"crossref","first-page":"10147","DOI":"10.18632\/oncotarget.23755","article-title":"Newly developed anti\u2010angiogenic therapy in non\u2010small cell lung cancer","volume":"9","author":"J Q","year":"2018","journal-title":"Oncotarget"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24223-1_5"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1154"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.022"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61719-5"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70586-2"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182166b6b"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-529"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S97235"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2712476"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28829"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2017.1323589"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16293"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01939.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.02.011"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_222_18"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2017.1414757"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003598"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19908"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90642-C"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023893931057"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S150555"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.081"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-669"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.3.2.263"},{"key":"e_1_2_7_45_1","article-title":"The role of VEGF in the regulation of physiological and pathological angiogenesis","author":"Ferrara N","year":"2005","journal-title":"EXS"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/1947601910392987"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i41.7478"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.01.015"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7948"},{"key":"e_1_2_7_50_1","first-page":"860259","article-title":"Xuebijing ameliorates sepsis\u2010induced lung injury by downregulating HMGB1 and RAGE expressions in mice","volume":"2015","author":"Wang Q","year":"2015","journal-title":"Evid Based Complement Alternat Med"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2015.51.4.2320599"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.07.037"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0913-7"},{"key":"e_1_2_7_54_1","first-page":"654","article-title":"An observational study of apatinib mesylate in treating advanced non\u2010small cell lung cancer with unknown driving gene(s)","volume":"23","author":"Fan S","year":"2018","journal-title":"J BUON"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2816737"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S139520"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009259"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22302-z"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S142686"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-31"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1759-7714.12898","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.12898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T09:06:56Z","timestamp":1694768816000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.12898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,19]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/1759-7714.12898"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.12898","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,19]]},"assertion":[{"value":"2018-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}